Bright Minds (DRUG) Fundamental Analysis: Revenue, Earnings & Valuation

6.62 / 10

Outperform

Fundamental rating is Outperform with a 6.6/10 score. Strengths include high Cash‑MV, strong inventory turnover, and robust asset‑MV. Weaknesses stem from elevated income‑tax‑to‑profit ratio and lower Revenue‑MV. Overall, the balance sheet and efficiency metrics support a positive outlook.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score1/3

Weight10.61%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight2.74%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight14.07%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.00%

1M Return-0.63%

PB-ROE

Value4.00

Score3/3

Weight22.07%

1M Return9.74%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.81%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight1.81%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight8.14%

1M Return4.32%

Asset-MV

Value-0.49

Score3/3

Weight29.87%

1M Return11.84%

Cash-MV

Value-0.09

Score2/3

Weight12.50%

1M Return5.94%

Is DRUG undervalued or overvalued?

DRUG scores 6.62/10 on fundamentals and holds a Discounted valuation at present. Backed by its -27.93% ROE, 0.00% net margin, -79.65 P/E ratio, 11.87 P/B ratio, and -165.67% earnings growth, these metrics solidify its Outperform investment rating.